These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 22312908)
21. Lipid glycation and protein glycation in diabetes and atherosclerosis. Miyazawa T; Nakagawa K; Shimasaki S; Nagai R Amino Acids; 2012 Apr; 42(4):1163-70. PubMed ID: 20957396 [TBL] [Abstract][Full Text] [Related]
22. Dermal microvessel density and maturity is closely associated with atherogenic dyslipidemia and accumulation of advanced glycation end products in adult patients with type 1 diabetes. Adamska A; Araszkiewicz A; Pilacinski S; Gandecka A; Grzelka A; Kowalska K; Malinska A; Nowicki M; Zozulinska-Ziolkiewicz D Microvasc Res; 2019 Jan; 121():46-51. PubMed ID: 30312628 [TBL] [Abstract][Full Text] [Related]
23. Recent progress in advanced glycation end products and diabetic complications. Vlassara H Diabetes; 1997 Sep; 46 Suppl 2():S19-25. PubMed ID: 9285494 [No Abstract] [Full Text] [Related]
24. Effect of glycation derived from α-dicarbonyl compounds on the in vitro digestibility of β-casein and β-lactoglobulin: A model study with glyoxal, methylglyoxal and butanedione. Zhao D; Le TT; Larsen LB; Li L; Qin D; Su G; Li B Food Res Int; 2017 Dec; 102():313-322. PubMed ID: 29195953 [TBL] [Abstract][Full Text] [Related]
25. Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis. Cantero AV; Portero-Otín M; Ayala V; Auge N; Sanson M; Elbaz M; Thiers JC; Pamplona R; Salvayre R; Nègre-Salvayre A FASEB J; 2007 Oct; 21(12):3096-106. PubMed ID: 17504976 [TBL] [Abstract][Full Text] [Related]
26. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Thornalley PJ Int Rev Neurobiol; 2002; 50():37-57. PubMed ID: 12198817 [TBL] [Abstract][Full Text] [Related]
27. Methylglyoxal and Advanced Glycation End Products in Patients with Diabetes - What We Know so Far and the Missing Links. Groener JB; Oikonomou D; Cheko R; Kender Z; Zemva J; Kihm L; Muckenthaler M; Peters V; Fleming T; Kopf S; Nawroth PP Exp Clin Endocrinol Diabetes; 2019 Sep; 127(8):497-504. PubMed ID: 28407670 [TBL] [Abstract][Full Text] [Related]
28. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300 [TBL] [Abstract][Full Text] [Related]
29. Dicarbonyls and Advanced Glycation End-Products in the Development of Diabetic Complications and Targets for Intervention. Brings S; Fleming T; Freichel M; Muckenthaler MU; Herzig S; Nawroth PP Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28475116 [TBL] [Abstract][Full Text] [Related]
30. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. Cooper ME Am J Hypertens; 2004 Dec; 17(12 Pt 2):31S-38S. PubMed ID: 15607433 [TBL] [Abstract][Full Text] [Related]
31. Methylglyoxal-derived hydroimidazolone-1 evokes inflammatory reactions in endothelial cells via an interaction with receptor for advanced glycation end products. Ishibashi Y; Matsui T; Nakamura N; Sotokawauchi A; Higashimoto Y; Yamagishi SI Diab Vasc Dis Res; 2017 Sep; 14(5):450-453. PubMed ID: 28631505 [TBL] [Abstract][Full Text] [Related]
32. Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study. Saremi A; Howell S; Schwenke DC; Bahn G; Beisswenger PJ; Reaven PD; Diabetes Care; 2017 Apr; 40(4):591-598. PubMed ID: 28148544 [TBL] [Abstract][Full Text] [Related]
33. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs). Yamagishi S; Matsui T Curr Drug Targets; 2010 Jul; 11(7):875-81. PubMed ID: 20412043 [TBL] [Abstract][Full Text] [Related]
34. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease. Bierhaus A; Ritz E; Nawroth PP Nephrol Dial Transplant; 1996; 11 Suppl 5():87-90. PubMed ID: 9044315 [TBL] [Abstract][Full Text] [Related]
35. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Wu L; Juurlink BH Hypertension; 2002 Mar; 39(3):809-14. PubMed ID: 11897769 [TBL] [Abstract][Full Text] [Related]
36. Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases? Nomiyama T J Atheroscler Thromb; 2020 Nov; 27(11):1139-1140. PubMed ID: 32507831 [No Abstract] [Full Text] [Related]
37. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Genuth S; Sun W; Cleary P; Gao X; Sell DR; Lachin J; ; Monnier VM Diabetes; 2015 Jan; 64(1):266-78. PubMed ID: 25187362 [TBL] [Abstract][Full Text] [Related]